The FDA has approved a new extended-release version of Oxycodone that contains abuse-deterrent properties. The drug, Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), is an extended-release/long-acting opioid to treat severe pain that requires daily treatment. Targiniq ER has properties that are expected to impede abuse of the drug by snorting and injection. When snorted or injected,Read more